Filings monitor · MRK

What Merck & Co., Inc.'s SEC filings said

10-Q for 2026Q3, filed 4 Nov 2026. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. Income Tax Rate Changes77 · importance in its document · 8-K exhibit · 29 Oct 2026
   The third-quarter 2026 GAAP effective income tax rate was 8.9%, down from 14.2% in the third quarter of 2025, reflecting favorable discrete items and the jurisdictional mix of income and expense. The non-GAAP effective tax rate was 10.9%…
2. Acquisitions and Divestitures71 · importance in its document · 10-Q · 2026Q3
   Merck acquired Cidara in January 2026 for $9.2 billion and Terns in May 2026 for $6.8 billion, including payments to settle share-based awards of $570 million and $606 million, respectively. The acquisitions added Cidara’s MK-1406…
3. Competition and Market Share63 · importance in its document · 10-Q · 2026Q3
   Generic competition drove significant declines in Januvia and Janumet sales after U.S. exclusivity ended in May 2026, and Janumet XR exclusivity ended in July; declines are expected to continue. Dificid sales fell 68% year over year as…
4. Liquidity and Debt Position60 · importance in its document · 10-Q · 2026Q3
   Cash and investments were $11.253 billion at September 30, 2026, down from $15.521 billion at December 31, 2025; working capital declined to $10.140 billion from $15.189 billion. Operating cash flow was $15.8 billion for the first nine…
5. Guidance raised60 · rule score among filings · 8-K Item 2.02 · 29 Oct 2026
   U.S. FDA Accepted for Priority Review a Biologics License Application Based on These Data o INTerpath-001 Trial Evaluating Intismeran Autogene Plus KEYTRUDA as Adjuvant Treatment for Patients With Resected Stage IIB-IV Melanoma, in…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 4 Nov 2026

Full report · Filing on EDGAR

• Acquisitions and DivestituresImportance 71
  Merck acquired Cidara in January 2026 for $9.2 billion and Terns in May 2026 for $6.8 billion, including payments to settle share-based awards of $570 million and $606 million, respectively. The acquisitions added…
• Competition and Market ShareImportance 63
  Generic competition drove significant declines in Januvia and Janumet sales after U.S. exclusivity ended in May 2026, and Janumet XR exclusivity ended in July; declines are expected to continue. Dificid sales fell 68%…
• Liquidity and Debt PositionImportance 60
  Cash and investments were $11.253 billion at September 30, 2026, down from $15.521 billion at December 31, 2025; working capital declined to $10.140 billion from $15.189 billion. Operating cash flow was $15.8 billion…
• WINREVAIR Demand GrowthImportance 59 · +2 more on this subject
  Winrevair sales rose 93% in the third quarter and 85% in the first nine months of 2026, largely reflecting higher demand and launch uptake in international markets. U.S. wholesaler and specialty pharmacy purchase…
• Vaccine Policy LitigationImportance 53 · +1 more on this subject
  In January 2026, the acting CDC director changed the U.S. child and adolescent immunization schedule, reducing routinely recommended vaccinations and introducing three recommendation categories. On March 16, 2026, a…
• Income Tax Rate ChangesImportance 52
  The effective tax rate was 8.9% in the third quarter of 2026, reflecting favorable discrete items and the jurisdictional mix of income and expense. For the first nine months of 2026, Merck recorded a $1.9 billion tax…
• Restructuring and Cost ReductionImportance 52
  Merck’s July 2025 restructuring program is expected to incur approximately $3.0 billion in cumulative pretax costs, about 60% cash, and generate approximately $1.7 billion in annual savings, substantially realized by…
• Research and Development ExpenseImportance 48
  Merck recorded a $5.7 billion research and development expense charge for the Terns asset acquisition in the first nine months of 2026, primarily for acquired in-process research and development with no alternative…
• Gross Margin DriversImportance 47
  Gross margin fell to 72.9% in the third quarter of 2026 from 77.7% in the third quarter of 2025, and to 73.6% in the first nine months of 2026 from 77.7% in the year-earlier period. Cost of sales increased 27% in the…
• Pricing and Market AccessImportance 46 · +1 more on this subject
  Merck reported that the government-set Medicare price for Januvia took effect on January 1, 2026, while negotiated prices for Janumet and Janumet XR are scheduled to take effect January 1, 2027. The company said the…
• German Health-Care ReformImportance 46
  Germany’s parliament approved the Statutory Health Insurance Contribution Rate Stabilization Act (GKV-BStabG) in July 2026. Most provisions take effect on January 1, 2027, and the company says the law will exert…
• IRS Tax DisputeImportance 46
  The IRS is examining Merck’s 2017 and 2018 tax returns, including the one-time transition tax enacted under the Tax Cuts and Jobs Act of 2017. In April 2025, Merck received Notices of Proposed Adjustment seeking…

8-K filings last 12 months

• Guidance raised29 Oct 2026 · 8-K Item 2.02 · Flagged · rule score 60
  “U.S. FDA Accepted for Priority Review a Biologics License Application Based on These Data o INTerpath-001 Trial Evaluating Intismeran Autogene Plus KEYTRUDA as Adjuvant Treatment for Patients With Resected Stage IIB-IV Melanoma, in…”
  Read from the attached exhibit: Income Tax Rate Changes · Acquisitions and Divestitures · Guidance / Outlook
• Board change13 Oct 2026 · 8-K Item 5.02 · Routine · rule score 10
  “The Board appointed Mr. Diaz as a member of both the Audit Committee and the Research Committee of the Board.”
• Results (release not read)4 Aug 2026 · 8-K Item 2.02 · Routine · rule score 20
  Read from the attached exhibit: Operating Expense Trends · Guidance / Outlook · Acquisition / Partnership / Divestiture
• Results, no stated guidance change30 Apr 2026 · 8-K Item 2.02 · Routine · rule score 10
• Results (release not read)3 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20

Earlier reports

• 10-Q · 2026Q2filed 7 Aug 2026
  Competition and Pricing Pressure · Liquidity and Debt Position · Acquisition / Partnership / Divestiture

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.